• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.一组同基因人类癌细胞为p53失活的癌症提出了一种治疗方法。
Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9. doi: 10.1073/pnas.0813333106. Epub 2009 Feb 18.
2
Synergistic two-step inhibition approach using a combination of trametinib and onvansertib in KRAS and TP53-mutated colorectal adenocarcinoma.在KRAS和TP53突变的结直肠癌中使用曲美替尼和昂凡塞替尼联合的协同两步抑制方法。
Biomed Pharmacother. 2025 Jan;182:117796. doi: 10.1016/j.biopha.2024.117796. Epub 2024 Dec 28.
3
p53-dependent repression of polo-like kinase-1 (PLK1).p53 依赖性对 Polo 样激酶-1(PLK1)的抑制。
Cell Cycle. 2010 Oct 15;9(20):4200-12. doi: 10.4161/cc.9.20.13532. Epub 2010 Oct 4.
4
Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.沃拉替尼(BI 6727)对波罗样激酶1的小分子抑制作用可导致体内黑色素瘤生长显著延迟并消退。
Cancer Lett. 2017 Jan 28;385:179-187. doi: 10.1016/j.canlet.2016.10.025. Epub 2016 Oct 25.
5
Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.联合检测PLK1、p21和p53免疫组化以预测TP53状态:乳腺癌的独立预后因素
Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386.
6
Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.细胞周期蛋白E1过表达使卵巢癌细胞对WEE1和PLK1抑制敏感。
Oncogene. 2025 May;44(19):1375-1386. doi: 10.1038/s41388-025-03312-4. Epub 2025 Feb 24.
7
Proteasome activation is critical for cell death induced by inhibitors of polo-like kinase 1 (PLK1) in multiple cancers.蛋白酶体激活对于多种癌症中 polo 样激酶 1(PLK1)抑制剂诱导的细胞死亡至关重要。
Eur J Pharmacol. 2024 Jun 5;972:176558. doi: 10.1016/j.ejphar.2024.176558. Epub 2024 Apr 15.
8
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer.在结直肠癌临床前模型中,MEK联合PI3K/mTORC1/2的治疗效果受TP53突变影响。
Clin Cancer Res. 2015 Dec 15;21(24):5499-5510. doi: 10.1158/1078-0432.CCR-14-3091. Epub 2015 Aug 13.
9
In vitro study of the Polo-like kinase 1 inhibitor volasertib in non-small-cell lung cancer reveals a role for the tumor suppressor p53.在非小细胞肺癌中研究 Polo 样激酶 1 抑制剂 volasertib 的体外研究揭示了肿瘤抑制因子 p53 的作用。
Mol Oncol. 2019 May;13(5):1196-1213. doi: 10.1002/1878-0261.12477. Epub 2019 Apr 5.
10
AMG 900, pan-Aurora kinase inhibitor, preferentially inhibits the proliferation of breast cancer cell lines with dysfunctional p53.AMG 900,一种泛 Aurora 激酶抑制剂,优先抑制 p53 功能失调的乳腺癌细胞系的增殖。
Breast Cancer Res Treat. 2013 Oct;141(3):397-408. doi: 10.1007/s10549-013-2702-z. Epub 2013 Oct 5.

引用本文的文献

1
The status of p53 affects the efficacy of PLK1 inhibitor BI6727 in prostate cancer cells.p53的状态影响PLK1抑制剂BI6727在前列腺癌细胞中的疗效。
Front Cell Dev Biol. 2025 Jul 30;13:1602693. doi: 10.3389/fcell.2025.1602693. eCollection 2025.
2
Ribosomal protein deficiencies linked to Diamond-Blackfan anemia induce distinctive alterations of ATF4 expression.与先天性纯红细胞再生障碍性贫血相关的核糖体蛋白缺陷会引起ATF4表达的显著改变。
iScience. 2025 Mar 1;28(4):112138. doi: 10.1016/j.isci.2025.112138. eCollection 2025 Apr 18.
3
Structural regulation of PLK1 activity: implications for cell cycle function and drug discovery.PLK1活性的结构调控:对细胞周期功能和药物发现的影响。
Cancer Gene Ther. 2025 May 16. doi: 10.1038/s41417-025-00907-7.
4
Onvansertib inhibits cell proliferation and increases sensitivity to paclitaxel in uterine serous cancer cells.奥万塞替布抑制子宫浆液性癌细胞的增殖并增加其对紫杉醇的敏感性。
Am J Cancer Res. 2025 Apr 15;15(4):1719-1732. doi: 10.62347/LIZG3616. eCollection 2025.
5
Charting the regulatory landscape of TP53 on transposable elements in cancer.绘制癌症中转座元件上TP53的调控图谱。
Genome Res. 2025 Jun 2;35(6):1456-1471. doi: 10.1101/gr.279398.124.
6
Cyclin E1 overexpression sensitizes ovarian cancer cells to WEE1 and PLK1 inhibition.细胞周期蛋白E1过表达使卵巢癌细胞对WEE1和PLK1抑制敏感。
Oncogene. 2025 May;44(19):1375-1386. doi: 10.1038/s41388-025-03312-4. Epub 2025 Feb 24.
7
Arginine Deprivation Induces Quiescence and Confers Vulnerability to Ferroptosis in Colorectal Cancer.精氨酸剥夺诱导结直肠癌进入静止期并使其易受铁死亡影响。
Cancer Res. 2025 May 2;85(9):1663-1679. doi: 10.1158/0008-5472.CAN-24-1940.
8
Robust p53 phenotypes and prospective downstream targets in telomerase-immortalized human cells.端粒酶永生化人类细胞中强大的p53表型及潜在下游靶点
Oncotarget. 2025 Feb 18;16:79-100. doi: 10.18632/oncotarget.28690.
9
Polo-like Kinase 1 Inhibitors Demonstrate In Vitro and In Vivo Efficacy in Preclinical Models of Small Cell Lung Cancer.Polo样激酶1抑制剂在小细胞肺癌临床前模型中显示出体外和体内疗效。
Cancers (Basel). 2025 Jan 28;17(3):446. doi: 10.3390/cancers17030446.
10
Challenges in the treatment of K601E-mutated lung carcinoma: a case report of rapid response and resistance to dabrafenib and trametinib.K601E 突变型肺癌治疗中的挑战:一例对达拉非尼和曲美替尼快速反应及耐药的病例报告
Front Oncol. 2024 Jul 8;14:1374594. doi: 10.3389/fonc.2024.1374594. eCollection 2024.

本文引用的文献

1
Aurora kinase A inhibition leads to p73-dependent apoptosis in p53-deficient cancer cells.极光激酶A抑制导致p53缺陷癌细胞中p73依赖的细胞凋亡。
Cancer Res. 2008 Nov 1;68(21):8998-9004. doi: 10.1158/0008-5472.CAN-08-2658.
2
Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors.新型Polo样激酶1抑制剂BI 2536在晚期实体瘤患者中的I期剂量递增及药代动力学研究。
J Clin Oncol. 2008 Dec 1;26(34):5511-7. doi: 10.1200/JCO.2008.16.1547. Epub 2008 Oct 27.
3
Kinase requirements in human cells: I. Comparing kinase requirements across various cell types.人类细胞中的激酶需求:I. 比较不同细胞类型间的激酶需求
Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16472-7. doi: 10.1073/pnas.0808019105. Epub 2008 Oct 23.
4
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.通过全基因组分析揭示的人类胰腺癌核心信号通路。
Science. 2008 Sep 26;321(5897):1801-6. doi: 10.1126/science.1164368. Epub 2008 Sep 4.
5
An integrated genomic analysis of human glioblastoma multiforme.多形性胶质母细胞瘤的综合基因组分析
Science. 2008 Sep 26;321(5897):1807-12. doi: 10.1126/science.1164382. Epub 2008 Sep 4.
6
The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies.MDM2抑制剂Nutlins作为治疗血液系统恶性肿瘤的一种创新治疗工具。
Curr Pharm Des. 2008;14(21):2100-10. doi: 10.2174/138161208785294663.
7
DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.DNA损伤检测与修复途径——癌症治疗中关卡激酶抑制剂的最新进展
Clin Cancer Res. 2008 Jul 1;14(13):4032-7. doi: 10.1158/1078-0432.CCR-07-5138.
8
Polo and Aurora kinases: lessons derived from chemical biology.Polo激酶和极光激酶:来自化学生物学的经验教训。
Curr Opin Cell Biol. 2008 Feb;20(1):77-84. doi: 10.1016/j.ceb.2007.11.008. Epub 2008 Jan 30.
9
Shaping genetic alterations in human cancer: the p53 mutation paradigm.塑造人类癌症中的基因改变:p53突变范例
Cancer Cell. 2007 Oct;12(4):303-12. doi: 10.1016/j.ccr.2007.10.001.
10
The genomic landscapes of human breast and colorectal cancers.人类乳腺癌和结直肠癌的基因组图谱。
Science. 2007 Nov 16;318(5853):1108-13. doi: 10.1126/science.1145720. Epub 2007 Oct 11.

一组同基因人类癌细胞为p53失活的癌症提出了一种治疗方法。

A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53.

作者信息

Sur Surojit, Pagliarini Raymond, Bunz Fred, Rago Carlo, Diaz Luis A, Kinzler Kenneth W, Vogelstein Bert, Papadopoulos Nickolas

机构信息

The Howard Hughes Medical Institute and The Ludwig Center for Cancer Genetics and Therapeutics, Baltimore, MD 21231, USA.

出版信息

Proc Natl Acad Sci U S A. 2009 Mar 10;106(10):3964-9. doi: 10.1073/pnas.0813333106. Epub 2009 Feb 18.

DOI:10.1073/pnas.0813333106
PMID:19225112
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2656188/
Abstract

Through targeted homologous recombination, we developed a panel of matched colorectal cancer cell lines that differ only with respect to their endogenous TP53 status. We then used these lines to define the genes whose expression was altered after DNA damage induced by ionizing radiation. Transcriptome analyses revealed a consistent up-regulation of polo-like kinase 1 (PLK1) as well as other genes controlling the G(2)/M transition in the cells whose TP53 genes were inactivated compared with those with WT TP53 genes. This led to the hypothesis that the viability of stressed cells without WT TP53 depended on PLK1. This hypothesis was validated by demonstrating that stressed cancer cells without WT TP53 alleles were highly sensitive to PLK1 inhibitors, both in vivo and in vitro.

摘要

通过靶向同源重组,我们构建了一组匹配的结肠癌细胞系,这些细胞系仅在内源性TP53状态方面存在差异。然后,我们使用这些细胞系来确定在电离辐射诱导的DNA损伤后其表达发生改变的基因。转录组分析显示,与具有野生型TP53基因的细胞相比,TP53基因失活的细胞中polo样激酶1(PLK1)以及其他控制G(2)/M期转换的基因持续上调。这导致了一个假设,即没有野生型TP53的应激细胞的存活依赖于PLK1。通过证明没有野生型TP53等位基因的应激癌细胞在体内和体外对PLK1抑制剂高度敏感,这一假设得到了验证。